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Background. Dendritic cells could be involved in immune surveillance of highly immunogenic tumors such as melanoma. Their
role in the progression melanocytic nevi to melanoma is however a matter of controversy.Methods.The number of dendritic cells
within epidermis, in peritumoral zone, and within the lesion was counted on slides immunohistochemically stained for CD1a,
CD1c, DC-LAMP, and DC-SIGN in 21 of dysplastic nevi, 27 in situ melanomas, and 21 invasive melanomas. Results. We found a
significant difference in the density of intraepidermal CD1c+ cells between the examined lesions; the mean CD1c cell count was
7.00/mm2 for invasive melanomas, 2.94 for in situ melanomas, and 13.35 for dysplastic nevi. The differences between dysplastic
nevi and melanoma in situ as well as between dysplastic nevi and invasive melanoma were significant. There was no correlation in
number of positively stained cells between epidermis and dermis. We did not observe any intraepidermal DC-LAMP+ cells neither
in melanoma in situ nor in invasive melanoma as well as any intraepidermal DC-SIGN+ cells in dysplastic nevi. Conclusion. It was
shown that the number of dendritic cells differs between dysplastic nevi, in situ melanomas, and invasive melanomas. This could
eventually suggest their participation in the development of melanoma.
1. Introduction
Cutaneousmalignantmelanoma is an aggressive human neo-
plasm, characterized by constantly increasing prevalence
rates and very high mortality. Additionally, despite advances
in melanoma treatment, the available therapeutic agents are
still not fully satisfactory for patients with advanced stages of
the tumor. These facts are prompting scientists to search for
new predictive markers and potential targets for melanoma
therapy. Cutaneous malignant melanoma is considered to be
one of the most immunogenic tumors [1] and it is sugges-
ted that circulating immunemarkers could correlate with the
overall prognosis of the patient [2]. Dendritic cells (DCs),
acting as professional antigen-presenting cells, play a key role
in the tumor-associated immunological reactions. They are
found in peripheral tissues and in immunological organs,
displaying considerable heterogeneity in phenotype, location,
and function [3–6]. On the basis of cell surface markers
and intracellular molecules, different subtypes of skin DCs
(Langerhans cells, dermal DC, plasmacytoid DC, and inflam-
matory dendritic epidermal cells) can be distinguished. The
surface receptors of different DCs subtypes determine their
ability to recognize, capture, and present tumor-associated
antigens to na¨ıve T cells in the context of major histocompat-
ibility molecules (MHCs), providing a bridge between innate
and adaptive immune responses [3, 7]. However, not only
do immature DCs fail to stimulate naı¨ve T cells to develop
into effective CD4+ or CD8+ lymphocytes, but they also
activate CD4+ CD25+ regulatory T cells, which enhance the
unresponsiveness of effector T cells in the tumor micro-
environment [8].
The role of DCs in development and propagation of vari-
ous human cancers including breast, colon, esophageal, lung,
and oral carcinoma [9–14] has been previously described.
However, the role of dendritic cells and their cutaneous
subtypes in the evolution of primary malignant melanoma
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Table 1: Antibodies used in the study.
Primary antibody Clone Dilution Antigen retrieval Incubation time Producer
CD1a MTB1 1 : 10 Citrate Overnight Novocastra (Leica Biosystems, Germany)
CD1c 5B8 1 : 200 EDTA 30min Abcam, UK
DC-LAMP Rabbit polyclonal 1 : 50 EDTA 30min Novus, USA
DC-SIGN 5D7 1 : 50 EDTA 30min Abcam, UK
remains to be confirmed as there are very few publications
addressing this issue. In the previous studies the differences
in distribution and phenotype of dendritic cells in intra- and
peritumoral area have been observed.Most of the DC subsets
found in melanoma cell nests were immature, suggesting
defects in maturation process of melanoma-associated den-
dritic cells [15–18]. Moreover, the degree of infiltration by
certain DCs has been considered to inversely correlate with
melanoma thickness [16].
Beside their possible prognostic value, evaluation of
dendritic cells might prove useful in designing new cell-
based immunotherapy for patients’ with advanced stages of
cutaneous melanoma [19]. The advances in identification
of tumor antigens facilitated the development of targeted
treatment and immunomodulation therapy, including the
use of patient’s dendritic cells. Such treatment is based on
increasing the capacity of the immune system to induce
tumor regression, where dendritic cells play a crucial role,
stimulating T cells to effective response against tumor-
associated antigens [19, 20]. Over the last few years ex vivo-
generated DCs [21] and in vivo-DC-targeting [22] have been
widely investigated as a potential therapeutic vaccine in
various types of cancers [23]. In humans, Food and Drug
Administration has already approved the targeted DC-based
immune therapy (sipuleucel-T vaccine) for prostate cancer
[6].
In the present study, we aimed to investigate the density
of dendritic cells expressing CD1a, CD1c, DC-SIGN, andDC-
LAMP. CD1a and CD1c are nonclassicalMHC class I antigens
[24]; the expression of CD1a is largely confined to DCs of the
human epidermis, whereas the presence of CD1c has been
observed in both dermal and epidermal cells [23]. DC-SIGN
is the C-type lectin receptor, regulating adhesion processes,
such as DC trafficking, transient T-cell binding, and antigen
capture [21, 25]. The expression of DC-LAMP, a lysosome-
associated membrane glycoprotein, defines mature dendritic
cells. The samples were obtained from 69 patients with one
of the following diagnosis: dysplastic nevus, melanoma in
situ, and invasive melanoma (level III or IV according to
Clark scale). DC density results were evaluated with regard
to the type of the melanocytic lesion, dendritic cells’ surface
markers, and maturation status as well as their association
with clinical characteristic of a patient. The obtained results
might prove useful in explaining the prognostic and pre-
dictive significance of dendritic cells infiltrating different
melanocytic lesions.
2. Materials and Methods
2.1. Tissue Specimens. We analysed 69 cutaneous samples
obtained between 2005 and 2014 from patients who were
diagnosed with dysplastic nevus, melanoma in situ, or
invasive melanoma. The paraffin-embedded samples were
obtained from the archives of the Department of Pathomor-
phology. Data concerning localization of the lesions as well as
patients’ sex and age were collected from the referrals for the
histopathological examination stored in the database of the
Department of Pathomorphology.
2.2. Immunohistochemistry. Immunohistochemistrywas per-
formed using the following monoclonal antibodies: CD1a,
CD1c, DC-LAMP, and DC-SIGN. Primary antibodies and
dilution as well as the retrieval procedure used in our study
are summarized in Table 1. Cutaneous tissue samples were
stained manually and processed according to the protocol
used on a routine basis in the laboratory of the Department
of Pathomorphology. The selected paraffin-embedded tissue
blocks were cut into 4 𝜇m thick sections, mounted on
SuperFrost glass slides (Thermo Scientific, USA), and dried
in an incubator for 12 hours in 34∘C.The obtained slides were
deparaffinized, dehydrated, and then incubated in 3% H
2
O
2
solution for 10 minutes to block endogenous peroxidase
activity. Antigen retrieval was performed by immersing the
slides in citrate buffer (pH 6.0; 0.01M) or EDTA (pH 8.0;
0.01M) and subjecting them to 97∘C in a water bath for 30
minutes.
Polyclonal secondary antibodies conjugated to horse-
radish peroxidase (HRP) enzyme (Ultra Vision LPValueDet-
ection System HRP Polymer, Lab Vision, Thermo Scien-
tific, USA) were applied to visualize the obtained antigen-
antibody complexes, using DAB (3,3󸀠-diaminobenzidine) as
chromogen. Cell nuclei were stained with hematoxylin to
enhance contrast in tissue sections.
2.3. Evaluation of Immunostaining. Quantitative assessment
of each DC subset was performed in light microscopy on the
basis of the numbers of positively stained cells (membrane
and cytoplasmic brown staining). The slides were firstly
examined at lowmagnification (10x lens) to select “hot spots”
of positively stained cells. Secondly, the number of positively
stained cells was counted at high magnification (40x lens)
and expressed per 1mm2. The number of dendritic cells was
evaluated in epidermis and in dermis separately, for each
monoclonal antibody independently in every cutaneous sam-
ple. In epidermis cells were counted above the tumor tissue,
in dermis in 0.5mm band of peritumoral tissue, or beneath
epidermis (in situ lesions). In dysplastic nevi and invasive
melanoma cases positively stained cells were also counted
in within and between nests of melanocytes (intratumoral
location). The obtained results were entered into Microsoft
Office Excel Spreadsheet (Microsoft Corporation, USA).
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Figure 1: Density of CD1c+ epidermal dendritic cells in nevi, in situ,
and invasive melanomas.
2.4. Statistical Analysis. Statistical data analysis was per-
formed using Statistica 10 software (StatSoft, USA). Rela-
tionships between the presence of each of the DC subsets
and patient’s sex were evaluated by using Mann–Whitney
U test. Spearman rank correlation was performed to assess
correlations between the numbers of respective DC subsets.
ANOVAKruskal-Wallis test was used to evaluate the relation-
ships between the content of respective DC subsets and the
type of melanocytic lesion. 𝑝 values ≤ 0.05 were considered
significant.
3. Results
The study group is comprised of 37 women and 32 men. The
mean age of patients at the time of diagnosis was 50.9 years
(ranging from 6 to 81 years).
Among 69 cases included in our study 21 (30.43%) were
classified as dysplastic nevi (compound, with moderate-to-
severe atypia), 27 (39.13%) as melanoma in situ, and 21
(30.43%) as invasivemelanoma.Themean tumor thickness in
invasivemelanoma groupwas 1.78mm (ranging from0.5mm
to 5.6mm).
There was no significant association between the ratio of
positively stained DCs (both in epidermis and in dermis) and
the sex as well as the age of a patient in any of the examined
DC subsets. There was also no correlation in number of
positively stained cells compared between epidermis and
dermis in each DC subset independently (𝑝 > 0.05 for all
the markers).
Mean value of CD1c+ cells was significantly higher in dys-
plastic nevi in comparison with both melanoma in situ and
invasive melanoma. The difference in intraepidermal CD1c+
cells number (𝑝 = 0.0003) between examined tissues was sta-
tistically significant. The differences were observed between
dysplastic nevi and melanoma in situ (𝑝 = 0.0003) as well as
between dysplastic nevi and invasive melanoma (𝑝 = 0.031)
(Figure 1). Mean value of CD1c+ cells was significantly higher
Figure 2: Dysplastic nevus. CD1c+ dendritic cells seen in epidermis
and dermis.
Figure 3: Invasive melanoma. DC-LAMP+ cells seen in dermis,
beneath the tumor mass.
in dysplastic nevi in comparison with both melanoma in
situ and invasive melanoma. No significant differences were
found in the content of DCs between the analysed types of
melanocytic lesions in case of CD1a+ cells (intraepidermal
and dermal), CD1c+ in dermis, DC-LAMP+ (intraepidermal
and dermal), and DC-SIGN+ (intraepidermal and dermal).
CD1a+ and CD1c+ cells were detected both in epidermis and
in dermis in all types of investigatedmelanocytic lesions (Fig-
ure 2). We did not observe any intraepidermal DC-LAMP+
cells neither in melanoma in situ nor in invasive melanoma
(Figure 3) as well as any intraepidermal DC-SIGN+ cells in
dysplastic nevi (Table 2).Therewere no significant differences
between dysplastic nevi and invasive melanomas regarding
number of DCs of any subset in intratumoral location. In that
location mean values of dendritic cell number in dysplastic
nevi versus invasive melanomas were, respectively, 14.72
versus 16.82 for CD1a, 32.00 versus 35.20 for CD1c, 1.0 versus
0.82 for DC-LAMP+, and 3.22 versus 4.00 for DC-SIGN+.
4. Discussion
DCs have attracted attention in recent years due to their
established prognostic and predictive value in various dis-
eases [26, 27] as well as potential usability in immunother-
apy strategies [19, 28–31]. Several authors have investigated
DC infiltration in cutaneous malignant melanoma samples
4 BioMed Research International
Table 2: Number of dendritic cells in epidermal and dermal compartment of dysplastic nevi and in situ and invasive melanomas.
Epidermal Dermal
Mean Range SD 𝑝 Mean Range SD 𝑝
CD1a
Invasive melanoma 38.24 0–80 21.63
0.2808 (NS)
22.55 0–53 14.79
0.2434 (NS)In situ melanoma 35.84 15–70 13.25 16.32 3–39 10.85
Dysplastic nevus 43.29 18–74 14.92 15.29 1–43 11.27
All cases 39.23 0–80 17.10 18.03 0–53 12.65
CD1c
Invasive melanoma 7.00 0–36 10.55
0.0003
51.81 6–96 30.79
0.0559 (NS)In situ melanoma 2.94 0–17 4.96 33.56 0–151 37.21
Dysplastic nevus 13.35 2–45 12.44 40.00 8–172 35.08
All cases 7.92 0–45 10.70 42.24 0–172 34.56
DC-LAMP
Invasive melanoma 0.00 0-0 0.00
0.3588 (NS)
1.26 0–10 2.62
0.2456 (NS)In situ melanoma 0.00 0-0 0.00 0.77 0–14 3.02
Dysplastic nevus 0.05 0-1 0.22 0.85 0–7 2.01
All cases 0.02 0-1 0.13 0.95 0–14 2.57
DC-SIGN
Invasive melanoma 0.10 0–2 0.45
0.5867 (NS)
11.89 0–39 13.54
0.2495 (NS)In situ melanoma 0.26 0–5 1.15 4.53 0–26 8.19
Dysplastic nevus 0.00 0-0 0.00 4.24 0–32 7.31
All cases 0.12 0–5 0.69 6.71 0–39 10.34
showing decreased number in advanced stages of the tumor
[16, 17, 32]. The others have noted a correlation of the
plasmacytoid DCs subset with tumor thickness and poor
prognosis [15, 33] and a positive correlation of density of DC-
LAMP+mature DCs with survival in univariate analysis [15].
Nonetheless, there are very few up-to-date studies investigat-
ing the significance of DCs in neoplastic melanocytic skin
lesions, quantifying various subsets and relative contribution
of epidermal and dermal DCs to host immunosurveillance.
Literature is also lacking in data concerning the infiltration
of dysplastic nevi by dendritic cells.
In our cohort of melanocytic lesion samples, we found
a statistically significant increase in the number of CD1c-
positive cells in the epidermis of melanoma in situ and
invasive tumors when compared with dysplastic nevi. Other
authors have also obtained similar results, showing the
depletion of intraepidermal DCs in melanoma [17, 32].
However, it should be mentioned that these other studies
looked at the DC number in general, as at that time the avail-
able immunochemistry was insufficient to precisely quantify
distinct DC subsets. The reason why these differences are
restricted to epidermis might be partly explained by distinct
origin and features of DCs in respective layers of the skin.
Langerhans cells (LCs), representing the DC population
found in epidermis, are considered to be of nonlymphoid
tissue origin, while dermal DCs derive from bone marrow
and blood-borne precursors [34].The lack of blood vessels in
epidermis together with the presence of basement membrane
may also be contributory. Moreover, it is suggested that some
melanoma-derived factors might adversely affect epidermal
Langerhans cells’ migration, differentiation, and function
[32]. For instance, TGF-beta and IL-10, found in melanoma
cell nests, have been described to reduce the development of
DCs [34, 35]. In addition, necrosis, regression, or scarring
of the tumor in more advanced stages may contribute to the
depletion of DCs in epidermis overlying this type of malig-
nant skin lesions [32]. Our finding indicates that epidermal
area of melanomas might not be adequately equipped with
CD1c-positive DC subset and thereby might be unable to
elicit an appropriate antitumor immune response. However,
whether the CD1c-positive cells depletion occurs during
the initiation, promotion, or progression of the tumor calls
needs further elucidation. There is also little available data
in the literature with regard to CD1c antibody and the exact
pathophysiological significance of this observation remains
to be established.
CD1a-positive DCs have been widely investigated in var-
ious human cancers with results varying between papers. We
did not observe any difference in CD1a-positive cells density
between epidermis anddermis in any of the investigated types
of melanocytic lesions. However, Lada´nyi et al. have shown
reduced number of intraepidermal CD1a-positive Langer-
hans cells overlying melanomas, suggesting that it could be
explained by the fact that even nonulcerated epidermis above
melanoma is often atrophic or hyperkeratotic. It has also been
reported that infiltration of CD1a-positive DC within tumor
cell nests and peritumoral area correlates with decreased
tumor thickness and the radial growth phase of melanomas,
respectively [16]. Vermi et al. observed the significant increase
in CD1a-positive cells accumulation in primary cutaneous
melanoma comparedwith normal skin andmelanocytic nevi;
in melanoma samples immature CD1a-positive DCs were
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mainly found in the dermis surrounding the tumor, in close
vicinity of lymphoid cell aggregates [18]. Recently, presence
of CD1a-positive DCs around the tumor cell nests was also
observed to correlate with the absence of hematogenous
spread in malignant melanoma of the skin [36]. In other
humanmalignancies the decreased number of CD1a-positive
DCs in tumor area is often associated with the progression of
the disease and unfavourable prognosis [11, 14].
DC-SIGN-positive DCs have recently emerged as
very potent cells shaping immune responses by mediating
immune recognition and cell adhesion [37]. Despite the
fact that our study did not reveal any statistically significant
differences in the density and distribution of this subset,
noteworthy is very low epidermal count of DC-SIGN-
positive DCs, as we have observed a few of them in only
two samples among all the investigated cases. We think that
this subset of DCs requires further investigation on a larger
sample of cases, especially as data concerning this marker
in melanocytic lesions is scarce and ambiguous. Although
DC-SIGN antibody is generally classified as nonspecific
marker of DC maturation [38], in one study on malignant
melanoma the expression of DC-SIGN and DC-LAMP was
found to be mutually exclusive, indicating that DC-SIGN
is expressed only by immature DCs. At the same time,
DC-SIGN-positive dermal DCs were noted to encompass
distinct subset compared to immature CD1a-positive DCs.
It should also be born in mind that DC-SIGN antibody may
stain positively other immune cells, such as certain subsets
of macrophages [18].
We have also noted the lack of mature DC-LAMP-
positive dendritic cells in epidermis of melanoma in situ and
invasive tumors and very low number of them in dermal
compartment. This is in agreement with findings from other
studies concerning various cancers, which highlight a sup-
pressive tumor influence on DCs function, as the infiltrating
cells in advanced stages of the disease are mostly immature
and thus unable to present effectively tumor-derived antigens
and mediate antitumor response [39–41]. The content of
DC-LAMP-positive DCs in primary cutaneous melanoma
was also found to be rather scarce and mostly confined
to the peritumoral lymphocyte infiltrate [15]. Mature DCs
were observed to form clusters with T cells, which could be
an evidence of a still ongoing immune response in tumor
microenvironment. It has also been shown that the degree
of DC-LAMP+ cells infiltration inversely correlates with
melanoma thickness and is associated with patients’ survival
[16].
The present study investigated only some problems
concerning the density of DCs in dysplastic and malig-
nant melanocytic lesions. It is still unclear whether the
differences in DC content and distribution patterns are a
cause or a result of neoplastic processes. Another interesting
question may arise with regard to the DCs subsets, whose
density and location do not differ significantly between
distinct melanocytic lesions, regardless of whether they
are of malignant nature or not. Do DCs fail to serve as
part of host immune system control due to some impair-
ment of functioning or should it be rather attributable to
the low immunogenicity of melanoma cells? Undoubtedly,
a thorough analysis of dendritic cell family, including a vari-
ety of markers and double staining procedures, is mandatory
to draw valid conclusions on the development of immunity
in the carcinogenesis of malignant melanoma. Moreover,
analysis of a large number of melanoma samples along
with the prospective study of clinical data could offer better
understanding of predictive and prognostic significance of
tumor-infiltrating DCs. Although our study requires further
validation, we believe that it sheds new light on the role
of DCs in dysplastic and neoplastic cutaneous lesions and
thus brings added value to the optimal patient care and
development of novel immunotherapy strategies.
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